drugset / Trial / NCT03283566

Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT

NCT03283566

RandomizedParallel-groupTriple-blindTreatment

Summary

This will be a pilot, 12-month phase II, open label, randomized, two-arm, single-blinded, placebo-controlled, parallel clinical trial of individuals undergoing TPAIT (Total Pancreatectomy and Autologous Islet Transplantation) for treatment of chronic pancreatitis (CP). The two study arms consist of HCQ-treated (Hydroxychloroquine) and placebo-treated individuals. The purpose of this study is to investigate the effects of HCQ administration compared to placebo on islet cell function post-autologous transplantation.

Timeline

Start
2017-10-03
Primary completion
2020-05-31
Completion
2020-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroxychloroquine Small molecule 200 mg